Gilder Gagnon Howe & Co. LLC raised its position in Nuvectra Corporation (NASDAQ:NVTR) by 12.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 953,431 shares of the company’s stock after buying an additional 105,580 shares during the period. Gilder Gagnon Howe & Co. LLC owned about 0.09% of Nuvectra Corporation worth $12,662,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Hodges Capital Management Inc. raised its stake in shares of Nuvectra Corporation by 18.6% in the second quarter. Hodges Capital Management Inc. now owns 227,807 shares of the company’s stock worth $3,025,000 after buying an additional 35,706 shares during the last quarter. Essex Investment Management Co. LLC raised its stake in shares of Nuvectra Corporation by 42.1% in the second quarter. Essex Investment Management Co. LLC now owns 202,623 shares of the company’s stock worth $2,691,000 after buying an additional 60,034 shares during the last quarter. Rockefeller Financial Services Inc. raised its stake in shares of Nuvectra Corporation by 3.2% in the second quarter. Rockefeller Financial Services Inc. now owns 107,523 shares of the company’s stock worth $1,428,000 after buying an additional 3,338 shares during the last quarter. FNY Partners Fund LP raised its stake in shares of Nuvectra Corporation by 15.1% in the first quarter. FNY Partners Fund LP now owns 98,200 shares of the company’s stock worth $670,000 after buying an additional 12,900 shares during the last quarter. Finally, Wells Fargo & Company MN raised its stake in shares of Nuvectra Corporation by 0.7% in the first quarter. Wells Fargo & Company MN now owns 112,997 shares of the company’s stock worth $772,000 after buying an additional 751 shares during the last quarter. Institutional investors and hedge funds own 59.91% of the company’s stock.

Shares of Nuvectra Corporation (NVTR) opened at 12.03 on Wednesday. The firm’s market cap is $124.41 million. Nuvectra Corporation has a 12-month low of $4.63 and a 12-month high of $15.00. The company’s 50 day moving average price is $12.60 and its 200-day moving average price is $9.03.

Nuvectra Corporation (NASDAQ:NVTR) last released its quarterly earnings results on Tuesday, August 8th. The company reported ($1.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.07. The firm had revenue of $7.20 million for the quarter, compared to the consensus estimate of $5.96 million. Nuvectra Corporation had a negative return on equity of 47.33% and a negative net margin of 286.26%. The firm’s quarterly revenue was up 188.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.85) EPS. On average, equities research analysts anticipate that Nuvectra Corporation will post ($4.87) EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Nuvectra Corporation (NVTR) Shares Bought by Gilder Gagnon Howe & Co. LLC” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/08/09/nuvectra-corporation-nvtr-shares-bought-by-gilder-gagnon-howe-co-llc.html.

A number of brokerages have recently weighed in on NVTR. Zacks Investment Research upgraded Nuvectra Corporation from a “sell” rating to a “hold” rating in a research note on Wednesday, July 12th. Piper Jaffray Companies restated a “neutral” rating and set a $14.00 price target on shares of Nuvectra Corporation in a research note on Thursday, July 6th. TheStreet upgraded Nuvectra Corporation from a “d” rating to a “c-” rating in a research note on Monday, June 19th. ValuEngine upgraded Nuvectra Corporation from a “sell” rating to a “hold” rating in a research note on Friday, June 16th. Finally, B. Riley restated a “buy” rating and set a $12.00 price target on shares of Nuvectra Corporation in a research note on Monday, May 15th. Three research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Nuvectra Corporation has an average rating of “Hold” and an average price target of $10.50.

In other news, CEO Scott F. Drees purchased 7,395 shares of the company’s stock in a transaction that occurred on Tuesday, May 30th. The shares were purchased at an average price of $10.41 per share, for a total transaction of $76,981.95. Following the purchase, the chief executive officer now directly owns 99,136 shares of the company’s stock, valued at approximately $1,032,005.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Scott F. Drees purchased 2,605 shares of the company’s stock in a transaction that occurred on Thursday, May 25th. The shares were purchased at an average price of $9.92 per share, for a total transaction of $25,841.60. Following the purchase, the chief executive officer now directly owns 90,041 shares in the company, valued at $893,206.72. The disclosure for this purchase can be found here.

About Nuvectra Corporation

Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company’s Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company’s commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs.

Want to see what other hedge funds are holding NVTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nuvectra Corporation (NASDAQ:NVTR).

Institutional Ownership by Quarter for Nuvectra Corporation (NASDAQ:NVTR)

Receive News & Ratings for Nuvectra Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra Corporation and related companies with MarketBeat.com's FREE daily email newsletter.